Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextran for postoperative hypercoagulability in lung cancer
ChiCTR2000036812Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dextran in bronchial carcinoma, pulmonary embolism (PE) and Postoperative hypercoagulability, sponsored by Shanghai General Hospital. Primary endpoint: D-dimer. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
dextran
03
Conditions
bronchial carcinomapulmonary embolism (PE)Postoperative hypercoagulability
Beyond the preview
Go deeper on ChiCTR2000036812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036812.